Pletal Related Published Studies
Well-designed clinical trials related to Pletal (Cilostazol)
Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype. [2011.04]
Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. [2011.04]
A randomized, double-blind, multicenter comparison study of triple antiplatelet therapy with dual antiplatelet therapy to reduce restenosis after drug-eluting stent implantation in long coronary lesions: results from the DECLARE-LONG II (Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions) trial. [2011.03.15]
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial. [2011.01.18]
Study design and rationale of "Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)" study: a double-blind randomised controlled multicenter clinical trial. [2011.01.12]
Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. [2011]
Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of
diabetes mellitus type 2 (ASCEND). [2011]
Impact of adjunctive cilostazol therapy on platelet function profiles in patients
with and without diabetes mellitus on aspirin and clopidogrel therapy. [2011]
Study design and rationale of "Synergistic effect of combination therapy with
cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)"
study: a double-blind randomised controlled multicenter clinical trial. [2011]
Results of the Cilostazol Stroke Prevention Study II (CSPS II), a randomized controlled trial for the comparison of cilostazol and aspirin in stroke patients. [2010.11]
[Effect of percutaneous coronary intervention timing and cilostazol use on left ventricular remodeling in patients with non-ST elevation myocardial infarction]. [2010.10]
Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention. [2010.10]
Periprocedural Cilostazol Treatment and Restenosis after Carotid Artery Stenting: The Retrospective Study of In-Stent Restenosis after Carotid Artery Stenting (ReSISteR-CAS). [2010.09.18]
The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. [2010.06.15]
Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. [2010.03]
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. [2010.02.01]
Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. [2010.02]
Effect of cilostazol on platelet aggregation in patients with non-ST elevation
acute coronary syndrome. [2010]
Addition of cilostazol reduces biological aspirin resistance in aspirin users
with ischaemic stroke: a double-blind randomized clinical trial. [2010]
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. [2009.12]
Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. [2009.11]
Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers. [2009.10]
Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. [2009.08]
Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation. [2009.05]
Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. [2009.05]
The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. [2009.05]
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. [2009.04]
The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. [2009.04]
Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. [2009.03.31]
The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. [2009.03]
The Vascular and Biochemical Effects of Cilostazol in Diabetic Patients With Peripheral Arterial Disease. [2009.01.11]
Efficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication. [2009.01.06]
The effects of cilostazol on peripheral neuropathy in diabetic patients with peripheral arterial disease. [2008.12]
Inhibition of platelet aggregation by combined therapy with aspirin and cilostazol after off-pump coronary artery bypass surgery. [2008.08]
Protective Effects of Cilostazol against Transient Focal Cerebral ischemia and Chronic Cerebral Hypoperfusion Injury. [2008.06]
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). [2008.02]
Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. [2008]
Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation. [2007.08.15]
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. [2007.08]
Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. [2007.05.03]
The effect of supervised exercise and cilostazol on coagulation and fibrinolysis in intermittent claudication: a randomized controlled trial. [2007.01]
Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: results from the Cilostazol for RESTenosis (CREST) trial. [2006.10]
A prospective randomized antiplatelet trial of cilostazol versus clopidogrel in patients with bare metal stent. [2006.03.05]
Effects of angiotensin-converting enzyme inhibitors or an angiotensin receptor blocker in combination with aspirin and cilostazol on in-stent restenosis. [2006.03]
Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. [2005.12.15]
Cilostazol in secondary prevention of stroke: Impact of the Cilostazol Stroke Prevention Study. [2005.11.03]
Coronary stent restenosis in patients treated with cilostazol. [2005.11.01]
RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. [2005.08]
Randomized comparison of cilostazol vs ticlopidine for antiplatelet therapy after coronary stenting. [2005.07]
Comparison of cilostazol and clopidogrel after successful coronary stenting. [2005.04.01]
Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. [2005.04]
Comparative inhibitory effects of cilostazol and ticlopidine on subacute stent thrombosis and platelet function in acute myocardial infarction patients with percutaneous coronary intervention. [2005.01]
Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. [2004.12]
Cilostazol, clopidogrel or ticlopidine to prevent sub-acute stent thrombosis: a meta-analysis of randomized trials. [2004.12]
The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. [2004.12]
Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. [2004.10.06]
Effects of antiplatelet agents on subacute thrombosis and restenosis after successful coronary stenting: a randomized comparison of ticlopidine and cilostazol. [2004.07]
Comparison of cilostazol and ticlopidine for one-month effectiveness and safety after elective coronary stenting. [2004.05]
Methods for the economic and quality of life supplement to the cilostazol for RESTenosis (CREST) trial. [2004.05]
Effects of cilostazol in patients with Raynaud's syndrome. [2003.12.01]
Effect of cilostazol on vasomotor reactivity in patients with vasospastic angina pectoris. [2003.07.01]
Cilostazol: a review of its use in intermittent claudication. [2003]
Failure of pentoxifylline or cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in claudication. [2002.09]
Randomized comparison of cilostazol versus ticlopidine hydrochloride for antiplatelet therapy after coronary stent implantation for prevention of late restenosis. [2002.08]
Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. [2002.03]
A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. [2002.02]
Cilostazol treatment of claudication in diabetic patients. [2002]
Differential lipogenic effects of cilostazol and pentoxifylline in patients with intermittent claudication: potential role for interleukin-6. [2001.10]
Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. [2001.09]
Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. [2001.04]
Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. [2001.01]
Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty. [2001.01]
Cilostazol: treatment of intermittent claudication. [2001.01]
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. [2001.01]
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. [2001]
A comparison of cilostazol and pentoxifylline for treating intermittent claudication. [2000.11]
Effects of cilostazol on angiographic restenosis after coronary stent placement. [2000.09.01]
Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. [2000.05.01]
Usefulness of cilostazol versus ticlopidine in coronary artery stenting. [1999.12.15]
Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction. [1999.11.01]
Comparison of cilostazol versus ticlopidine therapy after stent implantation. [1999.09.01]
Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. [1999.07.06]
Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin. [1999]
Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol. [1999]
Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. [1998.12]
Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. [1998.08.18]
Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation. [1998.08]
Effects of probucol and cilostazol alone and in combination on frequency of poststenting restenosis. [1998.07.15]
Impact of cilostazol on intimal proliferation after directional coronary atherectomy. [1998.03]
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. [1998.02]
Comparison of cilostazol with warfarin as antithrombotic therapy after femoro-popliteal bypass surgery using an ePTFE graft. [1997.11]
A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. [1997.09]
Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty. [1996.04]
Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. [1995.01]
Well-designed clinical trials possibly related to Pletal (Cilostazol)
A phase II dose-ranging study of the phosphodiesterase inhibitor K-134 in
patients with peripheral artery disease and claudication. [2012]
Application of adaptive design and decision making to a phase II trial of a phosphodiesterase inhibitor for the treatment of intermittent claudication. [2011.05.25]
Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions. [2011.04.01]
Efficacy and safety of combination antiplatelet therapies in patients with
symptomatic intracranial atherosclerotic stenosis. [2011]
Application of adaptive design and decision making to a phase II trial of a
phosphodiesterase inhibitor for the treatment of intermittent claudication. [2011]
Comparison of Triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and -LONG Trials). [2010.01.15]
Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans. [2009.07.01]
|
